{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:27:10Z","timestamp":1787041630008,"version":"build-2736575974"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019839","name":"Shenzhen Technology University","doi-asserted-by":"publisher","award":["GDRC202206"],"award-info":[{"award-number":["GDRC202206"]}],"id":[{"id":"10.13039\/100019839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20210324124008023"],"award-info":[{"award-number":["JCYJ20210324124008023"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119080","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:59:05Z","timestamp":1781827145000},"page":"119080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy"],"prefix":"10.1016","volume":"317","author":[{"given":"Huiheng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0723-6237","authenticated-orcid":false,"given":"Siyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119080_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1734-1140(11)70575-8","article-title":"Treatment of inflammatory bowel disease (IBD)","volume":"63","author":"Pithadia","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2026.119080_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3748\/wjg.v4.i5.446","article-title":"A. Pe?a, inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies","volume":"4","author":"Xia","year":"1998","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.119080_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119080_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/CMR.15.1.79-94.2002","article-title":"Clinical aspects and pathophysiology of inflammatory bowel disease","volume":"15","author":"Hendrickson","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119080_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/1751-2980.12449","article-title":"Epidemiology of inflammatory bowel diseases from west to east","volume":"18","author":"Vegh","year":"2017","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00384-024-04711-x","article-title":"Global, regional, and national burden of inflammatory bowel disease, 1990-2021: insights from the global burden of disease 2021","volume":"39","author":"Lin","year":"2024","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1186\/s12889-023-17431-8","article-title":"Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990-2050: a bayesian age-period-cohort modeling study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejmech.2026.119080_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ueg2.12317","article-title":"Implications of the changing epidemiology of inflammatory bowel disease in a changing world","volume":"10","author":"Agrawal","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"10.1016\/j.ejmech.2026.119080_bib12","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","article-title":"Conventional medical management of inflammatory bowel disease","volume":"140","author":"Burger","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.119080_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3904\/kjim.2022.152","article-title":"Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs","volume":"37","author":"Na","year":"2022","journal-title":"Korean J Intern Med."},{"key":"10.1016\/j.ejmech.2026.119080_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000535647","article-title":"Inflammatory bowel disease: from conventional immunosuppression to biologic therapy","volume":"42","author":"Sokic-Milutinovic","year":"2024","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.119080_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119080_bib17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119080_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J. Med. Life"},{"key":"10.1016\/j.ejmech.2026.119080_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","article-title":"Colorectal cancer in inflammatory bowel disease: mechanisms and management","volume":"162","author":"Shah","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.119080_bib20","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3748\/wjg.14.1972","article-title":"Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy","volume":"14","author":"Torres","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.119080_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050397","article-title":"Controlling gut inflammation by restoring anti-inflammatory pathways in inflammatory bowel disease","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119080_bib23","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.3748\/wjg.v25.i33.4796","article-title":"Role of NLRP3 inflammasome in inflammatory bowel diseases","volume":"25","author":"Tourkochristou","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.119080_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.smim.2014.02.009","article-title":"TNF and MAP kinase signalling pathways","volume":"26","author":"Sabio","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib25","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2026.119080_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.07.008","article-title":"Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease","volume":"79","author":"Chen","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2026.119080_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fimmu.2012.00245","article-title":"The role of the PI3K signaling pathway in CD4(+) T cell differentiation and function","volume":"3","author":"Han","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119080_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119080_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.728777","article-title":"The functions of BET proteins in gene transcription of biology and diseases","volume":"8","author":"Cheung","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.119080_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111849","article-title":"The bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins","volume":"17","author":"Taniguchi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v16071096","article-title":"A review of the bromodomain and extraterminal domain epigenetic reader proteins: function on virus infection and cancer","volume":"16","author":"Wu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119080_bib34","first-page":"23","article-title":"Bromodomain-containing protein 4 in inflammatory diseases: molecular mechanisms and therapeutic potential","author":"Frascatani","year":"2026","journal-title":"J. Inflamm."},{"key":"10.1016\/j.ejmech.2026.119080_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728222.2023.2175317","article-title":"Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics","volume":"27","author":"Ma","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2026.119080_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/bs.apha.2024.10.008","article-title":"BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease","volume":"101","author":"Ma","year":"2024","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib37","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/ecco-jcc\/jjae104","article-title":"Bromodomain-containing 4 is a positive regulator of the inflammatory cytokine response in the gut","volume":"18","author":"Franz\u00e8","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.ejmech.2026.119080_bib38","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/ibd\/izab190","article-title":"Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases","volume":"27","author":"Li","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","article-title":"Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation","volume":"151","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib40","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/acs.jmedchem.1c01851","article-title":"Discovery, X-ray crystallography, and anti-inflammatory activity of bromodomain-containing protein 4 (BRD4) BD1 inhibitors targeting a distinct new binding site","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib41","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: Scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/acsptsci.5c00068","article-title":"Orally bioavailable BRD4 BD1 inhibitor ZL0516 effectively suppresses colonic inflammation in animal models of inflammatory bowel disease","volume":"8","author":"Ma","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119080_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib45","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/13543784.2012.658915","article-title":"Phosphodiesterase inhibitors in inflammatory bowel disease","volume":"21","author":"Salari","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.119080_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11894-019-0689-2","article-title":"Novel non-biologic targets for inflammatory bowel disease","volume":"21","author":"Shukla","year":"2019","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.ejmech.2026.119080_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105030","article-title":"Blame the signaling: role of cAMP for the resolution of inflammation","volume":"159","author":"Tavares","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2004.06.008","article-title":"PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease","volume":"25","author":"Banner","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052638","article-title":"Inhibition of Phosphodiesterase-4 in psoriatic arthritis and inflammatory bowel diseases","volume":"22","author":"Picchianti-Diamanti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib51","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.intimp.2018.01.004","article-title":"Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP","volume":"56","author":"El-Ashmawy","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib53","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.gastro.2023.11.035","article-title":"Local bioactivation and efficacy of PALI-2108: a promising PDE4 inhibitor prodrug for ulcerative colitis treatment","volume":"166","author":"Bernard","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.119080_bib54","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1053\/j.gastro.2025.10.138","article-title":"PALI-2108, a colon targeted PDE4B inhibitor, rapidly restores immune-epithelial balance in ulcerative colitis throughgut-selective lymphocyte depletion","volume":"170","author":"Heyer","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2026.119080_bib55","first-page":"32","article-title":"PALI-2108, a colon targeted PDE4B inhibitor, rapidly restores immune-epithelial balance in ulcerative colitis throughgut-selective lymphocyte depletion","author":"Heyer","year":"2026","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.70005","article-title":"Safety, tolerability, and pharmacokinetics of mufemilast, a PDE4 inhibitor, in healthy participants: a first-in-human phase 1 study","volume":"15","author":"Li","year":"2026","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2026.119080_bib57","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1021\/acs.jmedchem.0c00060","article-title":"Discovery and optimization of \u03b1-Mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia","volume":"63","author":"Liang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114631","article-title":"Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of inflammatory bowel diseases","volume":"242","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113700","article-title":"Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin\/PDE4 inhibitors capable of inducing apoptosis at G2\/M phase arrest in glioma and lung cancer cells","volume":"224","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib60","doi-asserted-by":"crossref","first-page":"14502","DOI":"10.1021\/acs.jmedchem.0c00797","article-title":"Discovery and early clinical development of isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a novel \"Dual-Soft\" PDE4 inhibitor for topical treatment of atopic dermatitis","volume":"63","author":"Larsen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116710","article-title":"Discovery of novel N(2)-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease","volume":"277","author":"Zheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/imm.12597","article-title":"Innate immunity in vertebrates: an overview","volume":"148","author":"Riera Romo","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2026.119080_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/biology12040499","article-title":"Innate immune recognition, integrated stress response, infection, and tumorigenesis","volume":"12","author":"Kubelkova","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.ejmech.2026.119080_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100889","article-title":"The NLRP3 inflammasome: mechanism of action, role in disease and therapies","volume":"76","author":"Wang","year":"2020","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2026.119080_bib66","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cytogfr.2020.08.003","article-title":"Mechanisms of NLRP3 priming in inflammaging and age related diseases","volume":"55","author":"Gritsenko","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2026.119080_bib68","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061552","article-title":"The NLRP3 inflammasome as a critical actor in the inflammaging process","volume":"9","author":"Sebastian-Valverde","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119080_bib70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2019.00276","article-title":"NLRP3 inflammasome and inflammatory bowel disease","volume":"10","author":"Zhen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib71","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.immuni.2010.03.003","article-title":"The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis","volume":"32","author":"Zaki","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.119080_bib72","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ecco-jcc\/jjad164","article-title":"NLRP3 inhibition leads to impaired mucosal fibroblast function in patients with inflammatory bowel diseases","volume":"18","author":"Weber","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.ejmech.2026.119080_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116679","article-title":"NLRP3 inflammasome and its role in autoimmune diseases: a promising therapeutic target","volume":"175","author":"Ren","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119080_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149129","article-title":"A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of parkinson's disease","volume":"1842","author":"Chatterjee","year":"2024","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178117","article-title":"Usnoflast: a cutting-edge NLRP3 inhibitor attenuates colonic inflammation across diverse immunopathology","volume":"1006","author":"Sharma","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib76","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpdd.1162","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first-in-human phase 1 studies (single ascending dose and multiple ascending dose)","volume":"12","author":"Parmar","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2026.119080_bib77","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.2009.197822","article-title":"Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome","volume":"59","author":"Bauer","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.119080_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106231","article-title":"Inhibition of inflammatory mediators and cell migration by 1,2,3,4-tetrahydroquinoline derivatives in LPS-stimulated BV2 microglial cells via suppression of NF-\u03baB and JNK pathway","volume":"80","author":"Bui","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25112710","article-title":"One-pot multicomponent synthesis and bioevaluation of tetrahydroquinoline derivatives as potential antioxidants, \u03b1-Amylase enzyme inhibitors, anti-cancerous and anti-inflammatory agents","volume":"25","author":"Farooq","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119080_bib80","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/acs.jmedchem.0c01924","article-title":"Development of novel tetrahydroquinoline inhibitors of NLRP3 inflammasome for potential treatment of DSS-induced mouse colitis","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib81","doi-asserted-by":"crossref","first-page":"10168","DOI":"10.1021\/acs.jmedchem.4c00343","article-title":"Identification and validation of PKR as a direct target for the novel sulfonamide-substituted tetrahydroquinoline nonselective inhibitor of the NLRP3 inflammasome","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib82","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119080_bib83","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6543237","article-title":"The antimalarial chloroquine suppresses LPS-induced NLRP3 inflammasome activation and confers protection against murine endotoxic shock","volume":"2017","author":"Chen","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2026.119080_bib84","article-title":"Discovery, synthesis, and biological mechanism evaluation of novel quinoline derivatives as potent NLRP3 inhibitors","volume":"289","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib85","series-title":"Chemical Compounds, WO, 2018167468 A1","author":"Harrison","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119080_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117783","article-title":"Discovery of novel non-sulfonylurea NLRP3 inflammasome inhibitors for the treatment of multiple inflammatory diseases","volume":"295","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 inflammasome inhibitor, OLT1177 (Dapansutrile), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib88","doi-asserted-by":"crossref","first-page":"16612","DOI":"10.1021\/acs.jmedchem.4c01445","article-title":"Design, synthesis, and bioevaluation of novel NLRP3 inhibitor with IBD immunotherapy from the virtual screen","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejmech.2026.119080_bib90","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119080_bib91","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/acs.biochem.2c00310","article-title":"Targeted protein degradation via lysosomes","volume":"62","author":"Paudel","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119080_bib92","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41422-021-00532-7","article-title":"Degradation of lipid droplets by chimeric autophagy-tethering compounds","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116581","article-title":"Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD immunotherapy","volume":"275","author":"Yin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib94","series-title":"Encyclopedia of Life Sciences","article-title":"Signal transduction pathways in development: the JAK\/STAT pathway","author":"Naka","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119080_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119080_bib96","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119080_bib97","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"O'Shea","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.119080_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib99","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ibd\/izz266","article-title":"The JAK-inhibitor tofacitinib rescues human intestinal epithelial cells and colonoids from cytokine-induced barrier dysfunction","volume":"26","author":"Sayoc-Becerra","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib101","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(22)00778-4","article-title":"Upadacitinib for ulcerative colitis","volume":"399","author":"Ananthakrishnan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119080_bib102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.ejmech.2026.119080_bib103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17474124.2023.2172399","article-title":"A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis","volume":"17","author":"Law","year":"2023","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib104","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119080_bib105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17474124.2022.2138857","article-title":"Filgotinib for moderately to severely active ulcerative colitis","volume":"16","author":"Mannucci","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2026.119080_bib107","doi-asserted-by":"crossref","first-page":"138","DOI":"10.14309\/ajg.0000000000001979","article-title":"Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b\/3 SELECTION trial","volume":"118","author":"Danese","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.119080_bib108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/imt-2023-0116","article-title":"The role of filgotinib in ulcerative colitis and Crohn's disease","volume":"16","author":"Fanizza","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejmech.2026.119080_bib109","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"10","author":"Vermeire","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/toxsci\/kfac002","article-title":"Gut-selective design of orally administered izencitinib (TD-1473) limits systemic exposure and effects of Janus kinase inhibition in nonclinical species","volume":"186","author":"Hardwick","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib111","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of gut-selective pan-janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.ejmech.2026.119080_bib112","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1021\/jm4004895","article-title":"Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2","volume":"56","author":"Zak","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib113","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.jmedchem.9b01439","article-title":"Discovery of a gut-restricted JAK inhibitor for the treatment of inflammatory bowel disease","volume":"63","author":"Leonard","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib114","doi-asserted-by":"crossref","first-page":"11949","DOI":"10.1021\/acs.jmedchem.2c00390","article-title":"Discovery of novel Imidazo[4,5-c]quinoline derivatives to treat inflammatory bowel disease (IBD) by inhibiting multiple proinflammatory signaling pathways and restoring intestinal homeostasis","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib115","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.2741\/3908","article-title":"Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity","volume":"16","author":"Strobl","year":"2011","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.ejmech.2026.119080_bib116","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s11033-010-0601-5","article-title":"Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases","volume":"38","author":"Tao","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2026.119080_bib117","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/imt-2021-0096","article-title":"TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases","volume":"13","author":"Gonciarz","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejmech.2026.119080_bib118","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1248\/bpb.b21-00609","article-title":"Therapeutic advantage of Tyk2 inhibition for treating autoimmune and chronic inflammatory diseases","volume":"44","author":"Muromoto","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2026.119080_bib119","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jid.2025.05.014","article-title":"Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective, and potent allosteric TYK2 inhibitor","volume":"146","author":"Mehrotra","year":"2026","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/annrheumdis-2020-eular.1547","article-title":"THU0080 preclinical characterization of TLL018, a novel, highly potent and selective JAK1\/TYK2 inhibitor for treating autoimmune diseases","volume":"79","author":"Liu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib122","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/bjd\/ljaf185","article-title":"Safety and efficacy of the selective tyrosine kinase 2\/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study","author":"Chen","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib123","doi-asserted-by":"crossref","first-page":"10305","DOI":"10.1021\/acs.jmedchem.9b01348","article-title":"Discovery of potent and orally effective dual janus kinase 2\/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib124","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.jmedchem.0c01468","article-title":"Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors for the treatment of inflammatory bowel disease","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib125","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","article-title":"RIP kinases as modulators of inflammation and immunity","volume":"19","author":"He","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib126","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1038\/s41467-018-07447-9","article-title":"Structural basis of RIP2 activation and signaling","volume":"9","author":"Gong","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119080_bib127","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/acs.jmedchem.2c00604","article-title":"Discovery of potent and selective receptor-interacting serine\/threonine protein kinase 2 (RIPK2) inhibitors for the treatment of inflammatory bowel diseases (IBDs)","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib128","doi-asserted-by":"crossref","first-page":"17407","DOI":"10.1021\/acs.jmedchem.4c01313","article-title":"New potent RIPK2 inhibitors as a promising therapeutic avenue for colitis through the blockade of NOD inflammatory pathways","volume":"67","author":"Rivoal","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bbrc.2010.02.037","article-title":"Targeting of renal proximal tubule Na,K-ATPase by salt-inducible kinase","volume":"393","author":"Taub","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119080_bib130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1189\/jlb.2A0715-307R","article-title":"SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype","volume":"99","author":"Lombardi","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2026.119080_bib131","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.1113","article-title":"P0932 the first-in-class SIK3 inhibitor O3R-5671 demonstrates optimal pharmacokinetics and potent and sustained pharmacodynamic activity in human participants","volume":"20","author":"Kolb","year":"2026","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.ejmech.2026.119080_bib132","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1021\/acs.jmedchem.3c02246","article-title":"Discovery of clinical candidate GLPG3970: a potent and selective dual SIK2\/SIK3 inhibitor for the treatment of autoimmune and inflammatory diseases","volume":"67","author":"Peixoto","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115469","article-title":"Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment","volume":"256","author":"Cai","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib134","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1097-2765(03)00053-4","article-title":"Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members","volume":"11","author":"Janssens","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119080_bib135","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bcp.2010.06.020","article-title":"The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling","volume":"80","author":"Flannery","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119080_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102461","article-title":"IRAK family in inflammatory autoimmune diseases","volume":"19","author":"Su","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2026.119080_bib137","doi-asserted-by":"crossref","first-page":"10687","DOI":"10.1021\/acs.jmedchem.4c00202","article-title":"Fragment-based anti-inflammatory agent design and target identification: discovery of AF-45 as an IRAK4 inhibitor to treat ulcerative colitis and acute lung injury","volume":"67","author":"Zou","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib138","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1196\/annals.1326.036","article-title":"CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis","volume":"1072","author":"Williams","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119080_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102846","article-title":"CCR6-CCL20 axis as a therapeutic target for autoimmune diseases","volume":"20","author":"Meitei","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejmech.2026.119080_bib140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000320392","article-title":"Chemokines in inflammatory bowel diseases","volume":"28","author":"Atreya","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaut.2017.10.013","article-title":"CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation","volume":"88","author":"Kulkarni","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ejmech.2026.119080_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114703","article-title":"Discovery of small-molecules targeting the CCL20\/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases","volume":"243","author":"Martina","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2016.06.006","article-title":"CXCR4 signaling in health and disease","volume":"177","author":"Pozzobon","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2026.119080_bib144","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.apsb.2020.12.005","article-title":"An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation","volume":"11","author":"Harms","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119080_bib145","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000354229","article-title":"Current clinical indications for plerixafor","volume":"40","author":"Fruehauf","year":"2013","journal-title":"Transfus. Med. Hemotherapy"},{"key":"10.1016\/j.ejmech.2026.119080_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116605","article-title":"Discovery of novel CXCR4 inhibitors for the treatment of inflammation by virtual screening and biological evaluation","volume":"275","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib147","article-title":"Discovery of dibenzyl amide derivatives as novel CXCR4 modulators against inflammatory bowel disease","volume":"10","author":"Jiang","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"10.1016\/j.ejmech.2026.119080_bib148","doi-asserted-by":"crossref","first-page":"10057","DOI":"10.1021\/acs.jmedchem.4c00184","article-title":"Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-assisted Discovery of an Anti-IBD Lead Targeting CXCR4","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib149","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir. Care"},{"key":"10.1016\/j.ejmech.2026.119080_bib150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12968\/gasn.2021.19.1.28","article-title":"Steroids in inflammatory bowel disease: a clinical review","volume":"19","author":"Hussenbux","year":"2021","journal-title":"Gastrointest. Nurs."},{"key":"10.1016\/j.ejmech.2026.119080_bib151","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000354699","article-title":"Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates","volume":"31","author":"Curkovic","year":"2013","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2026.119080_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113468","article-title":"Discovery of novel 3-hydroxyandrosta-5,7-Diene-17-Carboxylic acid derivatives as anti-inflammatory bowel diseases (IBD) agents","volume":"220","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib153","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fimmu.2016.00406","article-title":"miRNA-124 in immune system and immune disorders","volume":"7","author":"Qin","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119080_bib154","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1073858417721150","article-title":"MicroRNAs: roles in regulating neuroinflammation","volume":"24","author":"Gaudet","year":"2018","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ejmech.2026.119080_bib155","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000560","article-title":"ABX464 (Obefazimod) upregulates miR-124 to reduce proinflammatory markers in inflammatory bowel diseases","volume":"14","author":"Apolit","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.119080_bib156","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.119080_bib157","article-title":"Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study","volume":"19","author":"Vermeire","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.ejmech.2026.119080_bib158","doi-asserted-by":"crossref","first-page":"14114","DOI":"10.1021\/acs.jmedchem.5c01398","article-title":"Novel small-molecule miR-124 inducer acts as \"a Physiological Brake\" of inflammation in ulcerative colitis by targeting the PIK3R2\/PI3K\/Akt axis","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119080_bib159","doi-asserted-by":"crossref","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front. Med. (Lausanne)"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:00:54Z","timestamp":1787040054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":159,"alternative-id":["S0223523426005258"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119080","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119080"}}